Biosimilars Could Cut Spending for Biologic Therapy in the U.S.
Increased market growth of biosimilars that are similar to brand-name biologic agents has the potential to reduce spending on prescription drugs
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.